Literature DB >> 25920607

Review of microRNA in osteosarcoma and chondrosarcoma.

Le Chang1, Swati Shrestha, Greg LaChaud, Michelle A Scott, Aaron W James.   

Abstract

MicroRNAs (miRNAs) are small noncoding RNAs, which play a complex role in posttranscriptional gene expression and can theoretically be used as a diagnostic or prognostic tool, or therapeutic target for neoplasia. Despite advances in the diagnosis and treatment of skeletal sarcomas, including osteosarcoma and chondrosarcoma, much remains unknown regarding their underpinning molecular mechanisms. Given the recent increasing knowledge base of miRNA roles in neoplasia, both as oncogenes and tumor suppressor genes, this review will focus on the available literature regarding the expression profiles and potential roles of miRNA in skeletal sarcomas. Although this is an emerging field, miRNA profiling may be of use in clarifying competing diagnoses of skeletal sarcomas and possibly indicate patient risk of resistance to traditional chemotherapeutic agents. While detecting and targeting miRNAs is currently limited to experimental investigations, miRNA may be utilized for future clinical management of skeletal sarcomas.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25920607     DOI: 10.1007/s12032-015-0613-z

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  92 in total

1.  MicroRNA cloning and sequencing in osteosarcoma cell lines: differential role of miR-93.

Authors:  Luisa Montanini; Lisa Lasagna; Valeria Barili; Søren Peter Jonstrup; Alba Murgia; Laura Pazzaglia; Amalia Conti; Chiara Novello; Jørgen Kjems; Roberto Perris; Maria Serena Benassi
Journal:  Cell Oncol (Dordr)       Date:  2011-09-30       Impact factor: 6.730

2.  miRNA-646 suppresses osteosarcoma cell metastasis by downregulating fibroblast growth factor 2 (FGF2).

Authors:  Xiao-hui Sun; Xiao-lin Geng; Jun Zhang; Chao Zhang
Journal:  Tumour Biol       Date:  2014-11-18

Review 3.  MicroRNAs in the pathogenesis of cancer.

Authors:  Francesca Lovat; Nicola Valeri; Carlo M Croce
Journal:  Semin Oncol       Date:  2011-12       Impact factor: 4.929

Review 4.  Current treatment of osteosarcoma.

Authors:  W S Ferguson; A M Goorin
Journal:  Cancer Invest       Date:  2001       Impact factor: 2.176

5.  Serum miR-195 is a diagnostic and prognostic marker for osteosarcoma.

Authors:  Haikang Cai; Hui Zhao; Jie Tang; Haishan Wu
Journal:  J Surg Res       Date:  2014-11-21       Impact factor: 2.192

Review 6.  The P53 pathway: what questions remain to be explored?

Authors:  A J Levine; W Hu; Z Feng
Journal:  Cell Death Differ       Date:  2006-06       Impact factor: 15.828

7.  Analysis of microRNAs expressions in chondrosarcoma.

Authors:  Teruhito Yoshitaka; Akira Kawai; Shigeru Miyaki; Kunihiko Numoto; Kazutaka Kikuta; Toshifumi Ozaki; Martin Lotz; Hiroshi Asahara
Journal:  J Orthop Res       Date:  2013-08-12       Impact factor: 3.494

8.  miR‑542‑3p overexpression is associated with enhanced osteosarcoma cell proliferation and migration ability by targeting Van Gogh‑like 2.

Authors:  Huazhuang Li; Hongtao Liu; Jingfang Pei; Haiyan Wang; Honglin Lv
Journal:  Mol Med Rep       Date:  2014-10-27       Impact factor: 2.952

9.  MicroRNA-29b-1 impairs in vitro cell proliferation, self‑renewal and chemoresistance of human osteosarcoma 3AB-OS cancer stem cells.

Authors:  Riccardo Di Fiore; Rosa Drago-Ferrante; Francesca Pentimalli; Domenico Di Marzo; Iris Maria Forte; Antonella D'Anneo; Daniela Carlisi; Anna De Blasio; Michela Giuliano; Giovanni Tesoriere; Antonio Giordano; Renza Vento
Journal:  Int J Oncol       Date:  2014-08-22       Impact factor: 5.650

10.  miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.

Authors:  Yong Zhou; Zufa Huang; Song Wu; Xiaofang Zang; Min Liu; Jian Shi
Journal:  J Exp Clin Cancer Res       Date:  2014-01-27
View more
  23 in total

Review 1.  Molecular genetics of osteosarcoma.

Authors:  Kirby Rickel; Fang Fang; Jianning Tao
Journal:  Bone       Date:  2016-10-17       Impact factor: 4.398

Review 2.  Mir-34a: a regulatory hub with versatile functions that controls osteosarcoma networks.

Authors:  Zhimin Yang; Tang Liu; Xiaolei Ren; Mei Yang; Chao Tu; Zhihong Li
Journal:  Cell Cycle       Date:  2022-06-14       Impact factor: 5.173

3.  CCL5 promotes VEGF-C production and induces lymphangiogenesis by suppressing miR-507 in human chondrosarcoma cells.

Authors:  Li-Hong Wang; Chih-Yang Lin; Shih-Chia Liu; Guan-Ting Liu; Yen-Ling Chen; Jih-Jung Chen; Chia-Han Chan; Ting-Yi Lin; Chi-Kuan Chen; Guo-Hong Xu; Shiou-Sheng Chen; Chih-Hsin Tang; Shih-Wei Wang
Journal:  Oncotarget       Date:  2016-06-14

4.  MiR-302b Suppresses Osteosarcoma Cell Migration and Invasion by Targeting Runx2.

Authors:  Yuanlong Xie; Wenchao Sun; Zhouming Deng; Xiaobin Zhu; Chao Hu; Lin Cai
Journal:  Sci Rep       Date:  2017-10-17       Impact factor: 4.379

5.  WISP-3 inhibition of miR-452 promotes VEGF-A expression in chondrosarcoma cells and induces endothelial progenitor cells angiogenesis.

Authors:  Chih-Yang Lin; Huey-En Tzeng; Te-Mao Li; Hsien-Te Chen; Yi Lee; Yi-Chen Yang; Shih-Wei Wang; Wei-Hung Yang; Chih-Hsin Tang
Journal:  Oncotarget       Date:  2017-06-13

6.  miR-200c and phospho-AKT as prognostic factors and mediators of osteosarcoma progression and lung metastasis.

Authors:  Pablo Berlanga; Lisandra Muñoz; Marta Piqueras; J Antoni Sirerol; María Dolors Sánchez-Izquierdo; David Hervás; Miguel Hernández; Margarita Llavador; Isidro Machado; Antonio Llombart-Bosch; Adela Cañete; Victoria Castel; Jaime Font de Mora
Journal:  Mol Oncol       Date:  2016-04-23       Impact factor: 6.603

7.  Tumor Suppressive Role of miR-342-5p in Human Chondrosarcoma Cells and 3D Organoids.

Authors:  Clément Veys; Abderrahim Benmoussa; Romain Contentin; Amandine Duchemin; Emilie Brotin; Jérôme E Lafont; Yannick Saintigny; Laurent Poulain; Christophe Denoyelle; Magali Demoor; Florence Legendre; Philippe Galéra
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

8.  Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest.

Authors:  Yong Zhao; Mei-Juan Tu; Wei-Peng Wang; Jing-Xin Qiu; Ai-Xi Yu; Ai-Ming Yu
Journal:  Sci Rep       Date:  2016-05-24       Impact factor: 4.379

9.  Leptin promotes VEGF-C production and induces lymphangiogenesis by suppressing miR-27b in human chondrosarcoma cells.

Authors:  Wei-Hung Yang; An-Chen Chang; Shih-Wei Wang; Shoou-Jyi Wang; Yung-Sen Chang; Tzu-Ming Chang; Shao-Keh Hsu; Yi-Chin Fong; Chih-Hsin Tang
Journal:  Sci Rep       Date:  2016-06-27       Impact factor: 4.379

10.  miR-143-3p inhibits the proliferation, migration and invasion in osteosarcoma by targeting FOSL2.

Authors:  Xiangran Sun; Guo Dai; Ling Yu; Qingzhu Hu; Jingteng Chen; Weichun Guo
Journal:  Sci Rep       Date:  2018-01-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.